THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) AS TREATMENT OF DEPRESSION IN PATIENTS WITH EPILEPSY
The current possibilities of treatment of depression in epilepsy were represented. Depression is one of the most frequent psychiatric comorbidities in epilepsy. The prevalence of depression ranges from 10 to 80%, and most often found in patients with focal epilepsy resistant to antiepileptic therapy. Depression in patients with epilepsy are not often diagnosed and therefore not treated. A number of common epilepsy and depression pathogenetic mechanisms, such as impaired metabolism of certain neurotransmitters in the central nervous system, especially serotonin was descripted. Based on this, the most promising drugs in the treatment of depression in epilepsy are now the selective serotonin reuptake inhibitor (SSRI), such as escitalopram. Objective. The primary objectives were to evaluate the efficacy and safety of escitalopram in treating depressive symptoms. Materials and methods. The study involved 68 patients aged 19-69 years with cryptogenic and focal epilepsy and different disease duration (from 5 to 21 years), different types of seizures and suffering depression interictal (between 2 and 5.5 years). Depression Rating Scale of Montgomery-Asberg (MADRS) was used. To assess the severity of the patient ’s condition at the time of the survey, a global assessment of disease severity (CGI-S) and the global assessment of the mental state (CGI-I) were used. While taking escitalopram (10-20 mg per day.), all patients received basic anticonvulsant therapy. Results. During follow-up the patients with epilepsy who took escitalopram, proconvulsant effect were not denoted. In assessing depressive symptoms improved markedly. Against the background of escitalopram no deterioration was marked, no sedation, addiction to the drug was observed, minimum drug interactions with anticonvulsants was registered. Conclusion. The results described observation program suggests a safe and effective treatment of escitalopram epilepsy patients with depression, it is well tolerated, low drugdrug interactions, as well as improve the quality of life of patients.
About the AuthorsYu. V. Solomatin
Solomatin Yury Viktorovich – Dr MSc, PhD.
Ul. Miklukho-Maklaya, 29-2, Mosow, Russia, 117485. Tel.: +74993464284
Yu. V. Rubleva
Rubleva Yulia Vladimirovna – postgraduate student.
Ul. Ostrovityanova, d. 1, Moscow, Russia, 117997. E-mail: email@example.com
1. Avakyan G. N. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 4: 46-49.
2. Blinov D. V. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2011; 2: 28-33.
3. Vorob’eva O. V. Lechenie zabolevanii nervnoi sistemy. 2014; 3 (15): 17-23.
4. Gusev E. I., Burd G. S., Nikiforov A. S. Neurological symptoms, syndromes, symptom and disease [Nevrologicheskie simptomy, sindromy, simptomokompleksy i bolezni (In Russian)]. Moscow. 1999; 691.
5. Kalinin V. V. Depression in epilepsy. Modern epileptology. Ed. EI Gusev, AB Hecht [Depressii pri epilepsii. Sovremennaya epileptologiya. Pod red. E. I. Guseva, A. B. Gekht (In Russian)]. Moscow. 2011; 299-311.
6. Karlov V. A. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 2: 71-79.
7. Kotov A. S. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 3: 58.
8. Lebedeva A. V., Melikyan E. G., Gekht A. B. Zhurn. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2011; 2: 50-56.
9. Lipatova L. V. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 20-27.
10. Mikhailov V. A. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 39-44.
11. Mosolov S. N. Clinical application of modern antidepressants [Klinicheskoe primenenie sovremennykh antidepressantov (In Russian)]. SPb. 1995; 565.
12. Sovremennaya epileptologiya: problem i resheniya. Pod red. E. I. Guseva, A. B. Gekht. M. 2015; 520.
13. Blanchet P., Frommer G. P. Mood change preceding epileptic seizures. J Nerv Ment Dis. 1986; 174: 471-476.
14. Blumer D., Herzog A. G., Himmelhoch J. et al. To what extent do premenstrual and interictal dysphoric disorders overlap? Significance for therapy. J Affect Disorders. 1998; 48: 215-25.
15. Blumer D. Dysphoric disorders and paroxysmal affects: recognition and treatment of epilepsy – related psychiatric disorders. Harvard Rev Psychiatry. 2000; 8: 8-17.
16. Borges Gonçalves E., Cendes F. Depression in patients with refractory temporal lobe epilepsy. Arq Neuropsiquiatr. 2011; 69 (5): 775-777.
17. Buchanan G. F. et.al. Serotonin neurones have anti-convulsant effects and reduc seizure-induced mortality. J Physiol. 2014 Oct 1; 592 (19): 4395-410.
18. Eddy M., Hugh E. Rickards, Andrea E. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011; 4 (6): 385-407.
19. Gilliam F. G., Santos J., Vahle V. et al. Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction? Epilepsia. 2004; 46 (2): 28-33.
20. Jacoby A., Baker G. A., Steen N. et al. The clinical course of epilepsy and ets psychosocial correlates: findings from a U.K. community study. Epilepsy. 1996; 37: 148-61.
21. Harden C. The co-morbidity of depression and epilepsy: epidemiology, etiology, and treatment. Neurology. 2002; 59 (6 suppl 4): 48-55.
22. Kanner A. M. Depression and Epilepsy: A New Perspective on Two Closely Related Disorders. Epilepsy Currents. 2006; 6 (5): 141-146.
23. Kanner A. M. Recognition of the various expressions of anxiety, psychosis, and aggression in epilepsy. Epilepsia. 2004; 45 (2): 22-7.
24. Kanner A. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry. 2003; 54: 388-398.
25. Kanner A. M., Balabanov A. Depression and epilepsy: how closely related are they? Neurology. 2002; 58 (8 suppl 5): 27-39.
26. Kanner A. M., Kozak A. M., Frey M. The use of sertralin in patients with epilepsy: is it safe Epilepsy Behav. 2000; 1 (2): 100-105.
27. Kanner A. M., Soto A. et al. Prevalence and clinical characteristic of postictal psychiatric symptoms in partial epilepsy. Neurology. 2004; 62: 708-713.
28. Kanner A. M., Wuu J. et al. A past psychiatric history may be a risk factor for topiramatrelated psychiatric and cognitive adverse events. Epilepsy Behav. 2003: 4: 548-552.
29. Maguire M. J. et.al. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev. 2014 Dec 3; 12.
30. Mendez M. F., Cummings J., Benson D. et al. Depression in epilepsy. Significance and phenomenology. Arch Neurol. 1986; 43: 766-770.
For citation: Solomatin Y.V., Rubleva Y.V. THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) AS TREATMENT OF DEPRESSION IN PATIENTS WITH EPILEPSY. Epilepsia and paroxyzmal conditions. 2016;8(3):11-18. https://doi.org/10.17749/2077-8333.2016.8.3.011-018
- There are currently no refbacks.